Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.

Cancer - 1 Jun 2026

Kessel Adam C, Kim Hayeon, Brown Paul D, Lehrer Eric J, Laack Nadia N, Mahajan Anita, Yan Elizabeth, Schultz Sydney E, Kizilbash Sani, Neth Bryan, Sener Ugur, Waddle Mark, Breen William G, Kowalchuk Roman O

Abstract excerpt

BACKGROUND: Vorasidenib is Food and Drug Administration-approved for treatment of grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas and has demonstrated a benefit in progression-free survival compared to a placebo. This study assessed the cost-effectiveness of this treatment strategy compared to standard treatment: observation or chemoradiation (CRT). METHODS: The authors used an integrated Markov model to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Markov Chains

Share to Quality-Adjusted Life Years

Share to Triazines

Source

Identifiers

PMID: 42159181
DOI: 10.1002/cncr.70463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.PMID 42159181Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Vorasidenib: First Approval.Semantic proximity Read ↗

Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan.Semantic proximity Read ↗

Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With a BRAF V600E Mutation Low-Grade Glioma in England and Wales.Semantic proximity Read ↗

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.Semantic proximity Read ↗

Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?Semantic proximity Read ↗

Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomasSemantic proximity Read ↗

Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United StatesSemantic proximity Read ↗

Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.